News

A U.S. man in his 60s developed cold agglutinin disease (CAD) as a rare complication of advanced pancreatic cancer, a case study reports. While CAD has been increasingly found to occur secondary to blood cancers, it is rarely associated with solid tumors. That may make treatment challenging…

While autoimmune hemolytic anemia (AIHA) — a group of disorders that includes cold agglutinin disease (CAD) — shares some immune features with other red blood cell-targeting diseases, its unique features might help researchers develop targeted therapies, a study reports. When analyzing the repertoire of immune B- and T-cell receptor…

A young girl developed cold agglutinin disease (CAD) secondary to a bacterial lung infection, due to Mycoplasma pneumoniae (M. pneumoniae), that resulted in progressive tissue death in her nose and limb extremities, according to a case report from Iran. The child’s condition did not respond to typical therapies aimed…

Laboratories testing for cold agglutinins — the self-reactive antibodies causing cold agglutinin disease (CAD) — need to use standard protocols to provide accurate results, compare results between studies, and guide treatment, researchers said. “International standardization of CA [cold agglutinin] testing for diagnostic use is essential,” the researchers wrote.

An underlying disorder involving abnormal cell growth turned out to be at the root of cold agglutinin disease (CAD) in a 78-year-old woman. The woman had monoclonal B-cell lymphocytosis (MBL), a condition that occurs when a group of identical white blood cells, in this case B-cells, grows abnormally, a…

The glucocorticoid prednisolone successfully treated a man’s primary cold agglutinin disease (CAD), which is typically resistant to such therapies, a case report said. “Occasional” primary CAD cases “have demonstrated a favorable response” to glucocorticoids, “highlighting the need for a flexible and individualized therapeutic approach,” the researchers wrote. The case…

In people with cold agglutinin disease (CAD), pretreatment with Enjaymo (sutimlimab-jome) may limit disease-associated complications following urgent or planned surgeries in which a patient’s body temperature is considerably decreased. That’s according to a new report detailing the case of an 80-year-old woman in Japan for whom Enjaymo treatment before an…

A woman with cold agglutinin disease (CAD) developed an aggressive B-cell lymphoma after having only a brief response to Enjaymo (sutimlimab), according to a case report. Researchers said the “case highlights the importance of reassessing underlying conditions through [a bone marrow biopsy] in cases where [Enjaymo] treatment is…

A new tablet formulation of Annexon Biosciences’ experimental therapy ANX1502 resulted in therapy levels in the blood that surpassed those expected to be effective in fasting participants with cold agglutinin disease (CAD). These results from a proof-of-concept study reflect a promising pharmacokinetic profile, which describes how the medication…

Cold agglutinin disease (CAD) secondary to Mycoplasma pneumoniae (M. pneumoniae) infection in adults is linked to severe illness, including a high risk of complications related to blood clots and intensive care admissions, according to a national study in France. Still, data showed that most patients recover within weeks with…